---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-075162"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2024-06-26T23:59:59+00:00"
generated_at: "2026-06-01T01:23:34.876040+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protagonist Therapeutics shareholders approve doubling of authorized common shares to 180M

## Summary
- Shareholders approved amendment to increase authorized common shares from 90M to 180M, effective June 21, 2024.
- Three Class II directors elected: Sarah O'Dowd, William Waddill, and Rusty Williams.
- Advisory vote on executive compensation approved: 33.9M for, 9.3M against.
- Ratification of Ernst & Young as independent auditor for FY2024 approved: 49.3M for, 115k against.
- All four proposals passed; no other matters submitted at annual meeting.

## SEC filing metadata
- accession: 0001104659-24-075162
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2024-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465924075162/0001104659-24-075162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465924075162/tm2418234d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-075162
- JSON: https://secwatch.observer/filing/0001104659-24-075162.json
- Plain text: https://secwatch.observer/filing/0001104659-24-075162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.